In vivo metabolic effects after acute activation of skeletal muscle Gs signaling

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

In vivo metabolic effects after acute activation of skeletal muscle Gs signaling. / Meister, Jaroslawna; Bone, Derek B J; Knudsen, Jonas Roland; Barella, Luiz F; Liu, Liu; Lee, Regina; Gavrilova, Oksana; Chen, Min; Weinstein, Lee S; Kleinert, Maximilian; Jensen, Thomas Elbenhardt; Wess, Jürgen.

I: Molecular Metabolism, Bind 55, 101415, 2022.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Meister, J, Bone, DBJ, Knudsen, JR, Barella, LF, Liu, L, Lee, R, Gavrilova, O, Chen, M, Weinstein, LS, Kleinert, M, Jensen, TE & Wess, J 2022, 'In vivo metabolic effects after acute activation of skeletal muscle Gs signaling', Molecular Metabolism, bind 55, 101415. https://doi.org/10.1016/j.molmet.2021.101415

APA

Meister, J., Bone, D. B. J., Knudsen, J. R., Barella, L. F., Liu, L., Lee, R., Gavrilova, O., Chen, M., Weinstein, L. S., Kleinert, M., Jensen, T. E., & Wess, J. (2022). In vivo metabolic effects after acute activation of skeletal muscle Gs signaling. Molecular Metabolism, 55, [101415]. https://doi.org/10.1016/j.molmet.2021.101415

Vancouver

Meister J, Bone DBJ, Knudsen JR, Barella LF, Liu L, Lee R o.a. In vivo metabolic effects after acute activation of skeletal muscle Gs signaling. Molecular Metabolism. 2022;55. 101415. https://doi.org/10.1016/j.molmet.2021.101415

Author

Meister, Jaroslawna ; Bone, Derek B J ; Knudsen, Jonas Roland ; Barella, Luiz F ; Liu, Liu ; Lee, Regina ; Gavrilova, Oksana ; Chen, Min ; Weinstein, Lee S ; Kleinert, Maximilian ; Jensen, Thomas Elbenhardt ; Wess, Jürgen. / In vivo metabolic effects after acute activation of skeletal muscle Gs signaling. I: Molecular Metabolism. 2022 ; Bind 55.

Bibtex

@article{7bd59ca586fd4f92984baa6feb70ff84,
title = "In vivo metabolic effects after acute activation of skeletal muscle Gs signaling",
abstract = "Objective: The goal of this study was to determine the glucometabolic effects of acute activation of Gs signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose homeostasis.Methods: To address this question, we studied mice that express a Gs-coupled designer G protein-coupled receptor (Gs-DREADD or GsD) selectively in skeletal muscle. We also identified two Gs-coupled GPCRs that are endogenously expressed by SKM at relatively high levels (β2-adrenergic receptor and CRF2 receptor) and studied the acute metabolic effects of activating these receptors in vivo by highly selective agonists (clenbuterol and urocortin 2 (UCN2), respectively).Results: Acute stimulation of GsD signaling in SKM impaired glucose tolerance in lean and obese mice by decreasing glucose uptake selectively into SKM. However, the acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors appear primarily mediated by altered insulin release. Clenbuterol injection improved glucose tolerance by increasing insulin secretion in lean mice. In SKM, clenbuterol stimulated glycogen breakdown. UCN2 injection resulted in decreased glucose tolerance associated with lower plasma insulin levels. The acute metabolic effects of UCN2 were not mediated by SKM Gs signaling.Conclusion: Selective activation of Gs signaling in SKM causes an acute increase in blood glucose levels. However, acute in vivo stimulation of endogenous Gs-coupled receptors enriched in SKM has only a limited impact on whole-body glucose homeostasis, most likely due to the fact that these receptors are also expressed by pancreatic islets where they modulate insulin release.",
keywords = "Faculty of Science, Skeletal muscle, GPCR, G protein, DREADD, Clenbuterol, Urocortin 2, Glucose homeostasis",
author = "Jaroslawna Meister and Bone, {Derek B J} and Knudsen, {Jonas Roland} and Barella, {Luiz F} and Liu Liu and Regina Lee and Oksana Gavrilova and Min Chen and Weinstein, {Lee S} and Maximilian Kleinert and Jensen, {Thomas Elbenhardt} and J{\"u}rgen Wess",
note = "Copyright {\textcopyright} 2021. Published by Elsevier GmbH.",
year = "2022",
doi = "10.1016/j.molmet.2021.101415",
language = "English",
volume = "55",
journal = "Molecular Metabolism",
issn = "2212-8778",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - In vivo metabolic effects after acute activation of skeletal muscle Gs signaling

AU - Meister, Jaroslawna

AU - Bone, Derek B J

AU - Knudsen, Jonas Roland

AU - Barella, Luiz F

AU - Liu, Liu

AU - Lee, Regina

AU - Gavrilova, Oksana

AU - Chen, Min

AU - Weinstein, Lee S

AU - Kleinert, Maximilian

AU - Jensen, Thomas Elbenhardt

AU - Wess, Jürgen

N1 - Copyright © 2021. Published by Elsevier GmbH.

PY - 2022

Y1 - 2022

N2 - Objective: The goal of this study was to determine the glucometabolic effects of acute activation of Gs signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose homeostasis.Methods: To address this question, we studied mice that express a Gs-coupled designer G protein-coupled receptor (Gs-DREADD or GsD) selectively in skeletal muscle. We also identified two Gs-coupled GPCRs that are endogenously expressed by SKM at relatively high levels (β2-adrenergic receptor and CRF2 receptor) and studied the acute metabolic effects of activating these receptors in vivo by highly selective agonists (clenbuterol and urocortin 2 (UCN2), respectively).Results: Acute stimulation of GsD signaling in SKM impaired glucose tolerance in lean and obese mice by decreasing glucose uptake selectively into SKM. However, the acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors appear primarily mediated by altered insulin release. Clenbuterol injection improved glucose tolerance by increasing insulin secretion in lean mice. In SKM, clenbuterol stimulated glycogen breakdown. UCN2 injection resulted in decreased glucose tolerance associated with lower plasma insulin levels. The acute metabolic effects of UCN2 were not mediated by SKM Gs signaling.Conclusion: Selective activation of Gs signaling in SKM causes an acute increase in blood glucose levels. However, acute in vivo stimulation of endogenous Gs-coupled receptors enriched in SKM has only a limited impact on whole-body glucose homeostasis, most likely due to the fact that these receptors are also expressed by pancreatic islets where they modulate insulin release.

AB - Objective: The goal of this study was to determine the glucometabolic effects of acute activation of Gs signaling in skeletal muscle (SKM) in vivo and its contribution to whole-body glucose homeostasis.Methods: To address this question, we studied mice that express a Gs-coupled designer G protein-coupled receptor (Gs-DREADD or GsD) selectively in skeletal muscle. We also identified two Gs-coupled GPCRs that are endogenously expressed by SKM at relatively high levels (β2-adrenergic receptor and CRF2 receptor) and studied the acute metabolic effects of activating these receptors in vivo by highly selective agonists (clenbuterol and urocortin 2 (UCN2), respectively).Results: Acute stimulation of GsD signaling in SKM impaired glucose tolerance in lean and obese mice by decreasing glucose uptake selectively into SKM. However, the acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors appear primarily mediated by altered insulin release. Clenbuterol injection improved glucose tolerance by increasing insulin secretion in lean mice. In SKM, clenbuterol stimulated glycogen breakdown. UCN2 injection resulted in decreased glucose tolerance associated with lower plasma insulin levels. The acute metabolic effects of UCN2 were not mediated by SKM Gs signaling.Conclusion: Selective activation of Gs signaling in SKM causes an acute increase in blood glucose levels. However, acute in vivo stimulation of endogenous Gs-coupled receptors enriched in SKM has only a limited impact on whole-body glucose homeostasis, most likely due to the fact that these receptors are also expressed by pancreatic islets where they modulate insulin release.

KW - Faculty of Science

KW - Skeletal muscle

KW - GPCR

KW - G protein

KW - DREADD

KW - Clenbuterol

KW - Urocortin 2

KW - Glucose homeostasis

U2 - 10.1016/j.molmet.2021.101415

DO - 10.1016/j.molmet.2021.101415

M3 - Journal article

C2 - 34883278

VL - 55

JO - Molecular Metabolism

JF - Molecular Metabolism

SN - 2212-8778

M1 - 101415

ER -

ID: 286994689